MERAZ 40mg IV Injection (Omeprazole) for Acid-Related Disorders | Pharma Services Group

MERAZ 40mg IV Injection contains Omeprazole as sodium equivalent to 40mg of Omeprazole and belongs to the proton pump inhibitor (PPI) class. It is an injectable formulation intended for patients in whom oral Omeprazole therapy is not appropriate. The available Pakistani product information confirms that Omeprazole 40mg injection is supplied as a powder for solution for infusion, with each vial containing Omeprazole sodium equivalent to 40mg Omeprazole.

Omeprazole 40mg IV injection reduces gastric acid secretion and is used as an alternative to oral therapy for conditions such as reflux esophagitis, symptomatic gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, NSAID-associated ulcers and Zollinger-Ellison syndrome. It works by inhibiting the gastric proton pump responsible for the final stage of acid production.

Key Benefits

\n
• Contains Omeprazole 40mg as the active ingredient.
\n
• Proton pump inhibitor (PPI) for effective gastric acid suppression.
\n
• Designed for intravenous use when oral therapy is inappropriate.
\n
• Used for GERD and acid-related gastrointestinal disorders.
\n
• Used in the management of gastric and duodenal ulcers.
\n
• May be used for NSAID-associated ulcers.
\n
• Can be used as part of treatment for certain H. pylori-associated peptic ulcers.
\n
• Available as a convenient sterile powder for IV administration.
\n

How It Works

Omeprazole is a proton pump inhibitor that specifically inhibits the H⁺/K⁺-ATPase enzyme, commonly called the gastric proton pump, in stomach parietal cells. This blocks the final step of gastric acid production and reduces both basal and stimulated acid secretion.

By significantly reducing stomach acid, Omeprazole helps relieve acid-related symptoms and supports healing of acid-damaged tissues such as the esophagus and stomach lining.

Uses / Therapeutic Applications

MERAZ 40mg IV Injection may be prescribed as an alternative to oral therapy for:

\n
• Gastroesophageal reflux disease (GERD)
\n
• Reflux esophagitis
\n
• Gastric ulcers
\n
• Duodenal ulcers
\n
• Prevention of relapse of gastric or duodenal ulcers
\n
• NSAID-associated gastric and duodenal ulcers
\n
• Prevention of NSAID-associated ulcers in patients at risk
\n
• H. pylori eradication therapy in combination with appropriate antibiotics
\n
• Zollinger-Ellison syndrome
\n
• Other clinically appropriate acid-related gastrointestinal conditions
\n

These indications are consistent with Pakistani regulatory product information for Omeprazole 40mg IV formulations.

Directions for Use

MERAZ 40mg IV Injection must be reconstituted and administered by a qualified healthcare professional. It is intended for intravenous administration and should not be self-administered.

For adult patients who cannot take oral therapy, regulatory product information lists Omeprazole IV 40mg once daily as a recommended alternative to oral therapy for the relevant indications. Administration is by intravenous infusion over approximately 20–30 minutes, according to the approved product instructions.

The exact dose, duration, preparation and administration method should be determined by the treating physician and the specific manufacturer's approved instructions.

Precautions

\n
• MERAZ 40mg IV Injection is a prescription medicine.
\n
• Tell your doctor if you have liver disease.
\n
• Inform your healthcare professional about all medicines and supplements you are taking.
\n
• Tell your doctor if you have unexplained weight loss, recurrent vomiting, difficulty swallowing, vomiting blood or black stools.
\n
• These symptoms may require further investigation before or during acid-suppressive treatment.
\n
• Tell your doctor if you have previously experienced an allergic reaction to Omeprazole or other proton pump inhibitors.
\n
• Long-term PPI treatment may be associated with changes in magnesium or vitamin B12 levels.
\n
• Use during pregnancy or breastfeeding only according to medical advice.
\n
• Do not administer the injection yourself.
\n

Possible Side Effects

Possible side effects of Omeprazole may include headache, diarrhea, constipation, abdominal pain, nausea, vomiting and flatulence. Other reactions can include dizziness, skin rash and changes in liver enzymes.

Seek immediate medical attention for serious allergic reactions, severe skin reactions, persistent severe diarrhea or other unusual symptoms.

Storage Instructions

\n
• Store according to the manufacturer's recommended conditions.
\n
• Protect the unopened vial from excessive heat, moisture and direct sunlight.
\n
• Keep in the original packaging until required for use.
\n
• Keep out of reach of children.
\n
• Do not use after the expiry date.
\n
• Reconstituted solution should be prepared, stored and administered according to the manufacturer's approved instructions.
\n

Manufacturer Information

Brand: MERAZ
Generic Name: Omeprazole
Strength: 40mg
Dosage Form: Powder for Solution for IV Infusion
Active Ingredient: Omeprazole Sodium equivalent to Omeprazole 40mg
Drug Class: Proton Pump Inhibitor (PPI)
Route: Intravenous (IV)

Important manufacturer note: The available Triafa Pharmaceuticals product listing confirms MERAZ 40mg CAPS and separately lists MERAZ INJ as Omeprazole injection, but it does not provide the injection strength on that listing. Therefore, the manufacturer/pack-specific details for the MERAZ 40mg IV injection should be verified from the physical injection packaging before publishing them as definitive.

Product Specifications